

Cover Story
COVID-19 & CancerFreeGuest Editorial
As the crisis triggered by the COVID-19 pandemic deepens, the two separate, unequal societies that make up the United States of America are equally frightened, bewildered, and unsure of what comes next.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer




















